Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 6/20 | 0.41 |
| ▸ | CCNK | O75909 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492736 | 1.00 | CDK9 (0.41) | CDK9CCNKCHEK1CCNT1PTGER4 | |
| SCHEMBL24270537 | 0.86 | SCN5A (0.41) | CDK9CCNT1SCN5A | |
| SCHEMBL29492760 | 0.86 | SCN5A (0.41) | CDK9CCNT1SCN5A | |
| SCHEMBL15749040 | 0.83 | CHEK1 (0.40) | CDK9CCNKCHEK1CCNT1PTGER4 | |
| SCHEMBL30578480 | 0.79 | PRKCQ (0.45) | CDK9CCNKCHEK1CCNT1PTGER4 | |
| SCHEMBL15749109 | 0.78 | MAPK1 (0.50) | CCNT1SCN5A | |
| SCHEMBL16042485 | 0.75 | PTGER4 (0.46) | CDK9CCNKCHEK1CCNT1PTGER4 | |
| SCHEMBL2578339 | 0.74 | PTGER4 (0.44) | PTGER4KCNH3KDR | |
| SCHEMBL15749007 | 0.73 | MAPK1 (0.41) | SCN5A | |
| SCHEMBL21207114 | 0.72 | KCNH3 (0.45) | CDK9CCNKCCNT1KCNH3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | CDK9 95/4885CCNK 18/4885CHEK1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.